JP2004516265A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516265A5
JP2004516265A5 JP2002550973A JP2002550973A JP2004516265A5 JP 2004516265 A5 JP2004516265 A5 JP 2004516265A5 JP 2002550973 A JP2002550973 A JP 2002550973A JP 2002550973 A JP2002550973 A JP 2002550973A JP 2004516265 A5 JP2004516265 A5 JP 2004516265A5
Authority
JP
Japan
Prior art keywords
naturally occurring
pharmaceutical formulation
formulation according
sterile pharmaceutical
egg lecithin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002550973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516265A (ja
Filing date
Publication date
Priority claimed from US09/745,018 external-priority patent/US6399087B1/en
Application filed filed Critical
Publication of JP2004516265A publication Critical patent/JP2004516265A/ja
Publication of JP2004516265A5 publication Critical patent/JP2004516265A5/ja
Pending legal-status Critical Current

Links

JP2002550973A 2000-12-20 2001-07-16 強化された微生物阻害を有するプロポフォール製剤 Pending JP2004516265A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/745,018 US6399087B1 (en) 2000-12-20 2000-12-20 Propofol formulation with enhanced microbial inhibition
PCT/US2001/022248 WO2002049631A1 (en) 2000-12-20 2001-07-16 Propofol formulation with enhanced microbial inhibition

Publications (2)

Publication Number Publication Date
JP2004516265A JP2004516265A (ja) 2004-06-03
JP2004516265A5 true JP2004516265A5 (https=) 2005-01-27

Family

ID=24994883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002550973A Pending JP2004516265A (ja) 2000-12-20 2001-07-16 強化された微生物阻害を有するプロポフォール製剤

Country Status (11)

Country Link
US (1) US6399087B1 (https=)
EP (1) EP1250130A4 (https=)
JP (1) JP2004516265A (https=)
CN (1) CN1359677A (https=)
AU (1) AU7592501A (https=)
BR (1) BR0109769A (https=)
CA (1) CA2397990A1 (https=)
MX (1) MXPA02008097A (https=)
RU (1) RU2244545C2 (https=)
UA (1) UA73970C2 (https=)
WO (1) WO2002049631A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
US20040171691A1 (en) * 2002-10-29 2004-09-02 Transform Pharmaceuticals, Inc. Propofol with cysteine
CN103405405A (zh) * 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US7468394B1 (en) * 2003-03-11 2008-12-23 Amphastar Pharmaceuticals, Inc. Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
RU2290169C1 (ru) * 2005-06-23 2006-12-27 Открытое Акционерное Общество "Фаберлик" Косметическое и/или дерматологическое средство и антиоксидант
KR101420445B1 (ko) 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
AU2006284657B2 (en) * 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
CN101411685B (zh) * 2007-10-19 2011-04-20 上海医药工业研究院 一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2661280T3 (en) * 2011-01-04 2019-03-04 Novaliq Gmbh O / V EMULSIONS INCLUDING SEMIFLUORINATED ALKANES
KR101946790B1 (ko) 2011-03-04 2019-02-13 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
CA2828635C (en) * 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
CN107397718A (zh) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
JP2013001700A (ja) * 2011-06-21 2013-01-07 Fujifilm Corp プロポフォール含有水中油型エマルション組成物
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
JP6247685B2 (ja) 2012-05-16 2017-12-13 メワ・シン 実質的に水不溶性の薬物の送達のための医薬組成物
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
DK3181119T3 (da) 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
EP3273953B1 (en) 2015-03-27 2019-01-02 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
US10821087B2 (en) * 2015-07-24 2020-11-03 Neon Laboratories Limited Stabilized injectable emulsion of Propofol and Ketamine
US11622937B2 (en) 2015-08-20 2023-04-11 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
MX2018003781A (es) 2015-09-30 2018-09-12 Novaliq Gmbh Compuestos semifluorados para administracion oftalmica.
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
PT3399962T (pt) 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (ko) 2018-03-28 2025-11-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
ES2211151T3 (es) * 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics

Similar Documents

Publication Publication Date Title
JP2004516265A5 (https=)
USD571471S1 (en) X-ray apparatus
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
NO20034149D0 (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
USD540568S1 (en) Shelves
ITTO20010005A0 (it) Formulazione farmaceutica.
MXPA03006884A (es) Formulacion farmaceutica.
JP2004210767A5 (https=)
MXPA03007641A (es) Formulacion farmaceutica.
MXPA03007215A (es) Formulaciones farmaceuticas.
PT1362027E (pt) 6,7,8,9-tetra-hidro-5h-benzociclo-heptenilaminas aciladas e a sua utilização como fármacos
JP2007522094A5 (https=)
PL375874A1 (pl) Wodne kompozycje farmaceutyczne 2,6-diizopropylofenolu
USD555241S1 (en) Straight handpiece
JP2007520565A5 (https=)
USD501508S1 (en) Pen
USD554923S1 (en) Table storage system
NO20030231D0 (no) Proteinkompleks som fungerer som en vehikkel for oralt administrerbare medikamenter
JP2004518665A5 (https=)
USD552738S1 (en) Clinical table
USD503883S1 (en) Packaging for a novelty gag gift
USD582615S1 (en) Exercise equipment for pets
USD554174S1 (en) Projector
USD553661S1 (en) Projector
USD526283S1 (en) Electrical rocker switch actuator